Yiqi-Shengjin Granules Clinical Trial Protocol for Hypertension and Glucose Metabolism

A randomized, double-blind, placebo-controlled clinical trial protocol registered as ChiCTR2200062453. The document details an 8-week study involving over 1,000 patients annually at Beijing Hospital of Traditional Chinese Medicine. It outlines endpoints including blood pressure, glucose metabolism, and cardiovascular event indicators.

Use Cases

• Analyzing clinical trial design for traditional Chinese medicine based on the described randomized, double-blind, placebo-controlled methodology.
• Studying combined drug efficacy endpoints based on the described primary and secondary outcome measures.
• Examining safety and efficacy assessment frameworks based on the described pre- and post-treatment evaluation schedule.

Strengths

• The protocol is registered with a public identifier (ChiCTR2200062453), enhancing traceability.
• The study design is explicitly detailed, including a 1:1 randomization ratio and an 8-week treatment period.
• The background cites over three decades of clinical use and an annual treatment cohort exceeding 1,000 patients.

Limitations

• The dataset is a 465.2 KB DOCX file containing only the study protocol, not the resulting clinical data.
• Column-level documentation for any potential trial data outputs is absent.
• Row count for any associated data is unknown, which may limit suitability assessment.

Provenance

Source

Haoyue Shi via figshare

Collection Method

Documented clinical trial study protocol.

Freshness

Last updated 2026-05-11 05:25:10; freshness should be verified.

Geography

Likely based at Beijing Hospital of Traditional Chinese Medicine.